Trump Administration Pushes Congress for Hemp and CBD Reforms, Treasury to Issue Cannabis Tax Guidance

President Trump is urging Congress to amend a law concerning hemp-derived CBD products, while the Treasury Department and IRS anticipate positive tax consequences from cannabis rescheduling and plan to issue new guidance. The FDA also announced steps to accelerate access to psychedelics following a presidential executive order.

Context

Hemp and CBD products have gained popularity in recent years, prompting discussions about their regulation. The current legal framework can be complex, as it varies between states and at the federal level. The FDA's recent actions to speed up access to psychedelics also indicate a broader reevaluation of cannabis-related substances.

Why it matters

The push for reforms on hemp and CBD products reflects a significant shift in federal policy towards cannabis. This could lead to increased economic opportunities in the hemp industry and affect consumer access to CBD products. Additionally, tax guidance from the Treasury Department may clarify financial implications for businesses involved in cannabis.

Implications

If Congress enacts reforms, it could lead to greater market stability and growth for hemp and CBD businesses. Clear tax guidance may encourage investment and compliance in the cannabis industry. The FDA's actions could also pave the way for further research and commercialization of psychedelic substances, impacting healthcare and therapeutic practices.

What to watch

Key developments will include Congress's response to the proposed amendments concerning hemp and CBD. The issuance of new tax guidance from the Treasury Department and IRS will be closely monitored by businesses in the cannabis sector. Additionally, the FDA's steps regarding psychedelics may signal future regulatory changes.